Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
Bottom Line: After the publication of the 10-year survival data from Milan on the adjuvant use of the block sequential regimen consisting of four cycles of adriamycin followed by eight cycles of intravenous CMF, many centres adopted this as standard of care for high risk, multiple node-positive breast cancer.At a median follow-up of 3 years, the overall 5-year disease-free survival is 61%, and the overall survival is 70%.These data confirm the efficacy of this regimen in non-trial patients, and, for the same high risk subgroup, indicate that this approach offers an outcome at least as good as that seen in the CALGB 9344 AC-Taxol arm, and the NCIC days 1 and 8 CEF.
Affiliation: Department of Oncology, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, Scotland, UK. David.Cameron@ed.ac.ukShow MeSH
Related in: MedlinePlus
Affiliation: Department of Oncology, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, Scotland, UK. David.Cameron@ed.ac.uk